High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

Najla El Jurdi, Heba Elhusseini, Joan D Beckman, Todd E. DeFor, Grigori Okoev, John Rogosheske, Aleksandr Lazaryan, Kristen Weiler, Veronika Bachanova, Brian C. Betts, Bruce R. Blazar, Claudio G Brunstein, Fiona He, Shernan G Holtan, Murali Janakiram, Radhika Gangaraju, Joseph Maakaron, Margaret L. MacMillan, Armin Rashidi, Erica D WarlickSmita Bhatia, Gregory Vercellotti, Daniel J Weisdorf, Mukta Arora

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with systemic inflammation and endothelial dysfunction, increasing risk for thromboembolic events (TEE). In 145 adult recipients who developed cGVHD after a matched sibling or umbilical cord blood donor HCT from 2010 to 2018, 32(22%) developed at least 1 TEE event, and 14(10%) developed 2 TEE events. The 5-year cumulative incidence of TEE was 22% (95% CI, 15–29%) with a median time from cGVHD to TEE of 234 days (range, 12–2050). Median time to the development of LE DVT or PE was 107 (range, 12–1925) compared to 450 days (range, 158–1300) for UE DVT. Cumulative incidence of TEE was 9% (95% CI, 0–20%), 17% (95% CI, 9–25%), and 38% (95% CI, 22–55%) in those with mild, moderate, and severe GVHD, respectively. Higher risk for TEE was associated with cGVHD severity (hazard ratio [HR] 4.9, [95% CI, 1.1–22.0]; p = 0.03), non-O-donor to recipient ABO match compared to O-donor to O-recipient match (HR 2.7, [95% CI, 1.0–7.5]; p = 0.053), and personal history of coronary artery disease (HR 2.4, [95% CI, 1.1–5.3]; p = 0.03). TEE was not associated with 2-year non-relapse mortality or 5-year overall survival.

Original languageEnglish (US)
Article number96
JournalBlood cancer journal
Volume11
Issue number5
DOIs
StatePublished - May 18 2021

Bibliographical note

Funding Information:
D.J.W.—research support from Incyte. B.R.B.—founder of Tmunity Therapeutics, advisory board member for Kadmon Pharmaceuticals, Magenta Therapeutics, and BlueRock Therapeutics and receives research funding from BlueRock Therapeutics. S.G.H.—consultant for Incyte. The remaining authors declare no competing interests.

Funding Information:
This research was supported by NIH grant P30 CA77598 utilizing the Biostatistics Core of the Masonic Cancer Center, University of Minnesota and the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR002494. We would like to acknowledge Michael Franklin, MS, for assistance in editing this manuscript.

Publisher Copyright:
© 2021, The Author(s).

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group'. Together they form a unique fingerprint.

Cite this